A Phase 4 interventional study of Total Hip Arthroplasty in Osteoarthritis, Osteonecrosis and Dysplasia; Hip, sponsored by Uppsala University. Recruiting at 1 site in Sweden. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Uppsala University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Osteoarthritis with a site in Sweden — 12 open to participants now, 25 under way, none of them phase 3. Osteoarthritis · Sweden.
Among the 78 studies in Osteoarthritis with a site in Sweden, this one is the 51st largest by planned enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 in phase 4, reaches primary completion later than 21 of the 24 other live ones, and was the 78th registered.
2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
Browse Osteoarthritis studies →12 of the 78 studies in Osteoarthritis with a site in Sweden are open now. Recruiting first, the newest first:
Sahlgrenska University Hospital · Sites in Sweden
Ages 18+ · Healthy volunteers
Vastra Gotaland Region · Sites in Sweden
Ages 30+
Uppsala University · Sites in Sweden
Ages 18–100
Karolinska Institutet · Sites in Sweden
University Hospital, Basel, Switzerland · Sites in Sweden, Austria, Croatia and 5 more countries
Ages 18–70
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 7 · Phase 4 5
First in 1997; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 80 across 2,242 interventional studies indexed under Osteoarthritis.
Median enrollment 98 across the 57 interventional studies, 500 across the 21 observational. Of the 42 that completed or were terminated, 12 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 78 have an industry lead sponsor. The 10 most frequent:
Uppsala University is the lead sponsor of 390 studies on the registry; 86 are open to participants now.
Uppsala University has 3 studies filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
3 of the studies in Osteoarthritis with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04210687Karolinska InstitutetTrapeziectomy vs. Trapeziometacarpal Limited Excision for Thumb Base Osteoarthritis | 2026-12-01 |
| NCT05584410Vastra Gotaland RegionDigitalization of Osteoarthritis Care | 2026-12-31 |
| NCT07383740Vastra Gotaland RegionTest-Retest Reliability of a Submaximal Exercise Test in Patients With Hip and Knee Osteoarthritis | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 78 studies in Osteoarthritis with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-centre, randomized, double-blinded controlled non-inferiority trial that will be conducted at the Orthopaedic Department at Uppsala University Hospital, Uppsala. The aim of the study is to evaluate the performance of a dual mobility acetabular component with a Vitamin E-infused highly crosslinked polyethylene (VEPE) liner compared to a conventional polyethylene (PE) liner in adult patients with symptomatic osteoarthritis, osteonecrosis, or dysplasia of the hip requiring a hip replacement. The assessments will focus on early wear, cup migration, adverse events, and clinical outcomes. Measurements will be conducted using Computed Tomography Radiostereometric Analysis (CT-RSA) instead of traditional radiostereometric analysis. The study hypothesis is that the PE liner will be non-inferior to the VEPE liner in terms of early wear over a two-year period.
Dual-mobility cups (DMCs) were introduced to reduce the risk of dislocation after total hip arthroplasty (THA) by improving stability while maintaining a large range of motion. Concerns remain regarding polyethylene liner wear due to the larger articulating surface, as wear rates exceeding 0.1 mm/year have been associated with osteolysis and aseptic loosening. Vitamin E-infused highly crosslinked polyethylene (VEPE) has been developed to improve wear resistance, and CT-based radiostereometric analysis (CT-RSA) provides a validated method for assessing implant wear and migration.
The BiMobile Dual Mobility System (Waldemar LINK GmbH) is designed to enhance stability and wear resistance through biocompatible materials and self-centering liners. Although clinical evidence specifically for the BiMobile cup is limited, studies of dual-mobility implants have reported low wear, limited migration, high implant survival, and low rates of loosening.
This study aims to evaluate the performance of the BiMobile dual-mobility cup with a VEPE liner compared with a conventional polyethylene (PE) liner. In a single-centre, randomized, double-blinded non-inferiority trial, patients undergoing THA will be followed for up to five years. The primary objective is to compare in vivo liner wear at two years using CT-RSA. Secondary objectives include evaluation of wear at five years, cup migration and fixation, patient satisfaction, adverse events, and patient-reported outcomes.
All participants will receive a BiMobile dual-mobility cup and will be randomized to either a VEPE or conventional PE liner. CT-RSA examinations will be performed postoperatively and at 6 months, 2 years, and 5 years to measure polyethylene wear, cup migration, and radiological signs of loosening. The study will provide important post-market evidence regarding the long-term safety, fixation, and wear characteristics of the BiMobile system and may help determine whether dual-mobility cups can be more widely used in younger and more active patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants are randomized to the BiMobile Dual Mobility System with a Vitamin E-infused highly crosslinked polyethylene (VEPE) liner (E-Dur, Waldemar Link GmbH, Hamburg, Germany).
Device: Total Hip Arthroplasty
Participants are randomized to the BiMobile Dual Mobility System with a conventional highly crosslinked polyethylene (PE) liner (Waldemar Link GmbH, Hamburg, Germany).
Device: Total Hip Arthroplasty
All patients will be operated with an anterolateral or posterior approach using a cemented or uncemented cup (BiMobile, Waldemar Link GmbH, Hamburg, Germany).
Wear performance
To compare the in vivo wear performance of a VEPE liner versus a conventional PE liner using CT-RSA in patients undergoing total hip arthroplasty with a dual mobility cup.
Time frame: Two years postoperatively.
Long-term wear performance
To evaluate the in vivo wear performance of the VEPE liner versus the conventional PE liner using CT-RSA.
Time frame: Five years postoperatively.
Cup stability
To evaluate stability of the cup by measuring degree of migration using CT-RSA.
Time frame: Two and five years postoperatively.
Harris Hip Score
Harris Hip Score (HHS), a clinician-completed tool scored from 0 to 100, will be used to evaluate hip function, pain, and mobility after hip replacement.
Time frame: Two and five years postoperatively.
Hip Disability and Osteoarthritis Outcome Score
The Hip Disability and Osteoarthritis Outcome Score (HOOS), a 40-item, patient-reported questionnaire, will be used to assess the participant's opinions about their hip symptoms and functional limitations.
Time frame: Two and five years postoperatively.
Patient Reported Outcome Scores
The EQ-5D form will be used to evaluate the participant's quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Time frame: Two and five years postoperatively.
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Oct 2033, 83 months after the start.
Of 54 non-industry phase 4 interventional studies under Osteoarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 60. This study's planned 83 months is above that.
Counting every sponsor, half of 63 studies reached it within 28 months; a quarter within 11 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.